ArticleBMC infectious diseases2026
Cytomegalovirus DNAemia in patients with anti-melanoma differentiation-associated gene 5 positive dermatomyositis from southern China.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCytomegalovirus (CMV) DNAemia represents a significant complication in patients with anti-melanoma differentiation-associated gene 5 positive dermatomyositis (anti-MDA5-positive DM). Here, we aimed to assess the prevalence and risk factors associated with CMV DNAemia in individuals with anti-MDA5-positive DM. Subsequently, we sought to evaluate the impact of CMV DNAemia on the 6-month mortality among these patients. Furthermore, we investigated the independent predictors of mortality in individuals with CMV DNAemia.
methodsUnivariate and multivariate logistic regression analyses were conducted to identify risk factors for the occurrence of CMV DNAemia. Kaplan-Meier curves and the Log Rank-test were employed to compare cumulative survival differences across various subgroups.
resultsAmong the 237 patients diagnosed with anti-MDA5-positive DM, 76 cases were classified into the CMV DNAemia-positive group, while the remaining 161 patients were categorized as the CMV DNAemia-negative group. Our study revealed that CMV DNAemia was associated with prior exposure to methylprednisolone pulse therapy, median to high doses of glucocorticoids, and the use of biological disease-modifying antirheumatic drugs, as well as increased levels of lactate dehydrogenase. However, there was no significant difference in 6-month mortality between the CMV DNAemia-positive and the CMV DNAemia-negative groups. Furthermore, our findings indicated that patients with CMV DNAemia who presented with rapidly progressive interstitial lung disease (RP-ILD), co-infection with other pathogens, and increased CMV loads exhibited higher 6-month mortality rates compared to those with non-RP-ILD, without co-infection, and with decreased CMV loads, respectively.
conclusionsCMV DNAemia is prevalent among patients with anti-MDA5-positive DM. However, it does not appear to significantly impact the 6-month mortality of these patients. CMV DNAemia can be effectively managed by identifying potential risk factors, monitoring viral loads dynamically, and initiating preemptive therapy timely.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.